Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
Date:2/7/2013

ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter
  • Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $59.3 million as of December 31, 2012.
  • "Avanir delivered another strong quarter of growth with record NUEDEXTA sales and prescriptions," said Keith A. Katkin , president and CEO of Avanir.  "In addition, the clinical team has successfully executed our plan to move our next generation asset, AVP-786, through the first stage of the phase I clinical study, with encouraging results. With demonstrated success in the AVP-786 study, we now have two promising assets in clinical development, each of which has broad potential in a number of CNS indications."

    Fiscal 2013 First Quarter Results

  • Total net revenues for the quarter ended December 31, 2012 were $16.5 million, compared with $7.2 million for the comparable quarter in fiscal 2012, representing 130% year-over-year growth. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $25.3 million in the first quarter of fiscal 2013, compared with $21.7 million in the comparable period in fiscal 2012.
  • Cash used in operations was $12.7
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... 2015 Microbrush International, a leading developer, producer ... restorative procedures, today announced the acquisition of DentiSmart ... sectional matrix system used in dental restorative procedures. ... opportunity to add DentiSmart to our growing portfolio ... VP and General Manager of Microbrush. "DentiSmart,s products ...
    (Date:5/4/2015)...  The board of directors of Eli Lilly and Company ... second quarter of 2015 of $0.50 per share on outstanding ... 10, 2015, to shareholders of record at the close of ... Company Lilly is a global healthcare leader that unites caring ... world. We were founded more than a century ago by ...
    (Date:5/4/2015)... , May 4, 2015 PAREXEL International Corporation ... presenting at the UBS Healthcare Conference on Monday, May 18, ... Vice President and Chief Financial Officer will be making a ... ET. A live webcast of the presentation will ... www.PAREXEL.com in the Upcoming Events portion of the ...
    Breaking Medicine Technology:Microbrush International Announces Acquisition of DentiSmart 2PAREXEL International to Present at UBS Healthcare Conference 2
    ... Manitoba - (May 31, 2007) Medicure Inc. ... that the results from its Phase 2 ... article in the June edition of The,Journal ... the,American Association of Thoracic Surgery., The article, ...
    ... --,EntreMed, Inc. , a clinical-stage pharmaceutical company ... inflammatory diseases,announced the presentation of preclinical results ... The data were,presented during oral and poster ... Kinases in Drug Discovery Conference,being held May ...
    Cached Medicine Technology:Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal 2Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal 3Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal 4EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3
    (Date:5/4/2015)... Greifensee, Switzerland (PRWEB) May 04, 2015 ... entitled “ The Importance of Data Integrity in ... Bob McDowall as guest presenter. This webinar will ... EDT (15:00 GMT). , Data integrity is a ... information submitted to regulatory agencies. However, in recent ...
    (Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 EY today ... Check as a finalist for the EY Entrepreneur Of ... The awards program recognizes entrepreneurs who demonstrate excellence ... performance and personal commitment to their businesses and communities. ... a panel of independent judges. Award winners will ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 Los ... now offering a more comfortable and attractive alternative for ... of choice for those who have lost teeth. Unfortunately, ... feel insecure or slip at the worst possible moment ... or talks. They can also painfully pinch or rub ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
    Breaking Medicine News(10 mins):Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2
    ... Washington, DC (August 21, 2008) It costs money ... environment changes or increases in staffing but those costs ... outcomes, according to research in a Special Issue of ... SAGE. , The guest editorial, "The Importance and Challenge ...
    ... can still take the cholesterol-lowering drug , , THURSDAY, ... said Thursday that they were investigating whether the ... , The U.S. Food and Drug Administration said ... was investigating a report from the so-called Simvastatin ...
    ... Calif., Aug. 22 Endocare, Inc.,(Nasdaq: ENDO ... an agreement with,its former CFO, John V. Cracchiolo, ... in exchange for Endocare,s waiver,of certain severance and ... 2008, the Company had budgeted over $875,000 for ...
    ... acne sufferer shares his way to how he cured his acne ... and stopped wasting money on expensive medications and over-the-counter products. ... ... Presents the scientifically proven method to http://www.acnefreein3daysinfo.com/ [cure acne] ...
    ... INDIANAPOLIS, Aug. 22 Eli Lilly and Co (NYSE:,LLY) ... approved the use of Cymbalta(R) (duloxetine) for the treatment ... for,duloxetine in Europe -- was issued on 28 July ... Agency,s (EMEA) Committee for,Medicinal Products for Human Use (CHMP) ...
    ... Hospira, Inc.,(NYSE: HSP ), a ... announced new national agreements with Premier Purchasing,Partners. ... member,hospitals with access to special pricing and ... infusion devices, related,sets and disposables, along with ...
    Cached Medicine News:Health News:The challenge of paying for quality nursing care 2Health News:FDA Investigates Possible Vytorin-Cancer Link 2Health News:FDA Investigates Possible Vytorin-Cancer Link 3Health News:Endocare and Former CFO Agree to Terminate Indemnification Agreement 2Health News:Chronic Acne Sufferer Finds a New Scientifically Proven Way to Permanently Clear Skin in 3 Days 2Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 2Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 3Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 4Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 5Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 6Health News:Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment 2
    ... Contoured Sole / Shock Absorption: , The ... and also results in a comfortable and natural ... return feature will absorb a significant portion of ... benefit is reduced pain and increased comfort during ...
    ... This versatile walker contains all the features ... the latest technology in rehabilitation care at an ... a graduated control of motion. Walker can be ... stops between 0 and 45 degrees of dorsi ...
    ... Intended to replace total contact casting ... preulcerative conditions of the plantar surface ... include moderate to severe plantar fasciitis ... and would benefit from even distribution ...
    ... The High Tide walker provides comfortable ... injuries of the lower leg, stress fractures ... stable fractures of the ankle. Extension pads ... larger patients.The shorter Low Tide walker with ...
    Medicine Products: